As a core lab, we provide a full range of neuroimaging endpoints designed to support clinical trials and patient care, enabling precise assessment of disease progression, treatment effects, and underlying biology. By integrating these endpoints, we help sponsors and clinicians obtain reliable, quantitative data that inform decision-making and advance therapeutic development.
The imaging measures can be obtained using magnetic resonance imaging (MRI), positron emission tomography (PET), computerized tomography (CT), magnetic resonance and digital subtraction angiography, optical coherence tomography (OCT) and ultrasound (Doppler) modalities.
Selecting and using the correct endpoint(s) for a given trial is vital to ensure that efficacy is not obscured, and to maximize statistical power. BNAC provides guidance in the selection of endpoints and expertise in calculating the most accurate and reproducible data possible. Many pre-existing datasets hold valuable information that can now be extracted with newer, more robust image analysis techniques. With state-of-the-art tools and use of artificial intelligence (AI), BNAC can quantitatively measure a variety of imaging outcomes using clinical trial, standardized, high-quality images, as well as clinical routine, non-standardized, low-quality images.

Anatomy, Atrophy, and Lesions – Comprehensive structural imaging for detecting and
monitoring disease:

  • Conventional T1/T2-weighted & FLAIR Imaging – standard structural sequences for assessing gray and white matter, lesion burden, and edema.
  • Volumetry – quantitative measurement of global and regional brain volumes to track atrophy over time.
  • Lesion Load & Distribution Analysis – automated and semi-automated tools for counting, segmenting, and characterizing lesions in the brain and spinal cord.
  • Longitudinal Tracking – assessment of structural changes across time points for disease progression and therapeutic response.
  • Morphometric Metrics – cortical thickness, subcortical volumes, and shape analysis to capture subtle neurodegenerative changes.                                                                                                                                                                                         

Nerve and Tissue Health – Quantitative metrics for microstructural integrity and disease progression:

  • Axonal Imaging – measurement of white matter integrity for neurodegenerative and demyelinating diseases.
  • Myelin Imaging – evaluation of myelination and remyelination in CNS disorders.

Advanced Imaging in Multiple Sclerosis – Sensitive markers of cortical and
microstructural pathology:

  • Quantitative Susceptibility Mapping (QSM) / Paramagnetic Rim Lesions (PRLs) – detection of iron-related microstructural changes and chronic active lesions.
  • Multi-Modal Cortical Lesion Enhanced (MMCLE) Technique – enables identification of cortical lesions across legacy datasets andin clinical routine.

Brain Function and Cognition – Mapping neural activity and connectivity to understand
functional impact:

  • Functional MRI (fMRI) – task-based and resting-state studies to monitor brain

activation patterns.

  • Connectomics – network-level analysis of brain connectivity and functional integration.

PET Imaging – Molecular and metabolic endpoints for translational and clinical research:

  • PET Imaging with Various Tracers – quantification of metabolism, inflammation, microglia activity, amyloid, tau, or other disease-specific molecular targets to inform pathophysiology and therapeutic evaluation.

For a detailed list of imaging analysis techniques and endpoints provided by BNAC, please see.